A461030 Share Price Performance
₩0
-8850.00 (-100.00%)
Price ₩0
Share Pricen/a
Analysis Article • Apr 16
IMB Dx, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A461030 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
IMB Dx, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -599.77
- 27.05%
- -150.13%
- 0%
About A461030
- Founded
- 2018
- Employees
- n/a
- CEO
- WebsiteView website
IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.
